Abzena appoints Jim Kennamer as SVP and Site Head of North Carolina

20th January 2022

 Cambridge, UK and San Diego, CA, January 20, 2022 – Abzena, a leading Partner Research Organization (PRO) for biopharmaceutical outsourced solutions from concept to clinic and into GMP manufacturing has announced the appointment of Jim Kennamer as Senior Vice President and Site Head of North Carolina.

Jim has a Bachelor of Science Degree in Biochemistry from Oklahoma State University in Stillwater, Oklahoma and a Doctor of Philosophy, Biochemistry also from Oklahoma State University.

With over 30 years’ experience in the Pharmaceutical industry, Jim has held various positions with increasing levels of responsibilities at Boehringer Mannheim Biochemical, Roche Molecular Biochemicals, Diosynth, Strategene, and Talecris Biotherapeutics/Grifols Therapeutics.  For the past six years, he has been the Vice President of Global Manufacturing Operations for Immucor in Norcross Georgia.

Jim has deep experience with manufacturing operations and processes, particularly in process improvements.   He has driven regulatory compliance and audit readiness for multiple regulatory agencies established complex supply agreements and has driven LEAN and right-first-time operations throughout his organizations.    Jim previously sat on the North Carolina State University Biotechnology Training and Education Center (BTEC) Advisory Board.




Notes to editors

About Abzena

Abzena is a leading partner research organization that offers discovery, design, development and cGMP manufacture of biologics, bioconjugates, and complex or highly potent small molecules to the global biopharmaceutical industry. From its facilities in the UK and US, the company provides its customers with concept to clinic solutions. Abzena is owned by Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors. For more information, please see www.abzena.com.